Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.
AMCP submits comments to CMS on the Medicare Part D MTM Program Standardized Format urging CMS to work with the pharmacy profession to modernize, test, and validate alternate formats to maximize its intended benefit for Medicare beneficiaries and to work towards implementing a new standardized format in advance of 2020.
AMCP submits comments to CMS regarding implementation of the drug management program provisions of CARA.
AMCP submits comments on 21st Century Cures Act supporting the inclusion of ‘Section 3037 – Health Care Economic Information’ that would modernize FDAMA Section 114.
AMCP submits comments in response to PQA Endorsement Consideration of Two New Performance Measures: Concurrent Use of Opioids and Benzodiazepines and Adherence to Non-Infused Disease Modifying Agents Use to Treat Multiple Sclerosis.
AMCP requests meeting with the Office of Management and Budget to discuss the impact of the SAMSHA pending final rule on Confidentiality of Substance Use Disorder Patient Records (42 CFR Part 2).
AMCP submits comments on USP’s Draft Medicare Model Guidelines v7.0.
AMCP submits comments to the Pennsylvania Senate Appropriations Committee opposing House Bill 1698, which would mandate coverage for abuse deterrent opioid analgesic drug products.
AMCP submits comments to FDA on BsUFA II reauthorization, citing a need for robust biosimilars education, expeditious and harmonious guidance documents, and post-market surveillance.
AMCP submits comments on ICER Abuse-Deterrent Opioids: Draft Scoping Document on critically evaluating effectiveness and value of ADFs.
AMCP submits comments on ICER Value Assessment Framework to further enhance the utility and relevance of the value assessment framework to managed care pharmacy.
AMCP requests California Governor Jerry Brown sign Assembly Bill 1114, which would make certain pharmacist provided services a covered benefit under the Medi-Cal program.
AMCP submits comments to the California Senate, urging support for Assembly Bill 1114, which would make certain pharmacist provided services a covered benefit under the Medi-Cal program.
AMCP joins eight other pharmacy organizations in comments to the FDA on PDUFA VI reauthorization, commending the FDA for its continued focus on patient safety and quality patient care.
AMCP submits comments to the Massachusetts Joint Committee on Health Care Financing, supporting House Bill 2041, a bill that would recognize pharmacists as health care providers and authorize them to perform certain patient services.
AMCP submits comments to the Massachusetts House of Representatives, opposing House Bill 976, which amends the state's biosimilar law by replacing the words “biosimilar and interchangeable” in the definition of
“interchangeable biologic product” with the words “therapeutically equivalent to”.
AMCP submits comments to the California Senate Committee on Health, opposing Assembly Bill 2050, which would mandate medication synchronization.
AMCP submits comments to FDA on Biosimilars Labeling Draft Guidance Advocating for Changes to the Biosimilarity Statement and Biosimilar Product Identification & Naming Sections.
AMCP Joins Other Organizations Urging Senate Not to Approve Legislative Provision to Remove Requirement for USP Monographs for Biologics and Biosimilars.
AMCP publishes a summary of the provisions in the Comprehensive Addiction and Recovery Act of 2016 (CARA) that are relevant to AMCP members. CARA is a major piece of legislation that creates a framework for opioid abuse prevention and treatment.
AMCP joins 27 health care organizations to support amending current law consistent with HIPAA allowing plans to access patient addiction records.
AMCP submits comments to the NJ Assembly Health and Senior Citizens Committee, supporting Assembly Bill 3982, a bill that mandates practitioners issue prescriptions for controlled substances electronically using an electronic health records system.
AMCP Submits Comments for the Record on Senate Finance Committee Hearing Titled “Examining the Proposed Medicare Part B Drug Demonstration”
AMCP Summary - Medication Assisted Treatment for Opioid Use Disorders
AMCP submits comments in support of CMS Medicare Part D Reporting Requirements for CY2017
AMCP submits comments to the Massachusetts Joint Committee on Health care Financing, supporting SB 2313, which establishes a task force to study payer practices regarding the dispensing of specialty drugs. AMCP recommends that the Committee support this bill with language including a managed care pharmacist as a member on the task force.
AMCP Summary – MedPAC June 2016 Report to Congress
AMCP and Other Pharmacy Organizations’ Joint Comments to CMS on New Physician Payment Proposed MACRA Rule Reflect Changing Role of Pharmacists
AMCP submits comments to the Michigan Senate Health Policy Committee, supporting SB 1024, a bill that extends payer and provider access to Michigan’s electronic system for monitoring schedule 2-5 controlled substances.
AMCP submits comments to the New York Senate Insurance Committee, opposing S. 3419c, a bill mandating requirements for a medical exceptions process.
AMCP submits comments to the North Carolina House Insurance Committee, opposing HB 1048, a bill mandating coverage for ADF-Opioids and requirements for a medical exceptions process.
AMCP submits comments on AHRQ draft technical brief related to MAT for opioid abuse disorders commending AHRQ for recognizing the important role that pharmacists can play in MAT.
AMCP joins 10 other stakeholders in letter to FDA advocating for the removal of the biosimilarity statement on labeling for biosimilar products.
AMCP submits comments on SAMHSA proposed rule related to medication assisted treatment for opioid abuse disorders urging for provisions related to team-based care, education on diversion mitigation strategies, and the expansion of practitioner eligibility for DATA waivers.
AMCP, APhA and NCPA submit joint comments on SAMHSA proposed
rule related to medication assisted treatment (MAT) for opioid abuse disorders
urging for advancement of the pharmacist’s role in MAT to improve access and
AMCP continues to support final passage of S. 524 The Comprehensive Addiction and Recovery Act. The House has requested a conference with the Senate to resolve differences and appointed conference committee members.
AMCP submits comments to the Massachusetts Joint Committee on Health Care Financing, opposing HB 791, a bill concerning Step Therapy.
AMCP and other stakeholders express support for the use of drug management programs in Medicare as part of S. 524 – the Comprehensive Addiction and Recovery Act (CARA).
AMCP submits comments to the Ohio Senate Health and Human Services Committee, opposing Sub. HB No. 505, a bill concerning biosimilars.
AMCP submits comments to Illinois House leadership, opposing HB 2743, a bill concerning abuse-deterrent opioid analgesic drug products.
AMCP submits letter to New Hampshire Governor Hassan urging her to Veto HB 1608, a bill concerning multiple prior authorization forms.
AMCP joins other stakeholders to
oppose language in S. 2700 that would exempt biological medicines from the
requirement to adhere to USP public standards for quality.
AMCP submits comments to Ohio House leadership, opposing HB 248, a bill concerning abuse-deterrent opioid analgesic drug products
AMCP Submits Comments for the Record on Energy & Commerce Subcommittee on Health Hearing Titled “The Obama Administration’s Medicare Drug Experiment: The Patient and Doctor Perspective”
AMCP submits comments to CMS in response to proposed Part B drug payment model, urging CMS to carefully consider comments received and to release a revised proposed rule with an opportunity for additional stakeholder feedback prior to finalization and adoption.
AMCP submits comments on Hawaii HB 254 concerning biosimilars
AMCP submits comments on Minnesota Senate File No. 2536 to House Committee Leadership on Prior Authorization
AMCP submits comments on Minnesota Senate File No. 2536 to Senate Committee Leadership on Prior Authorization
AMCP Comments - S.2700 - FDA and NIH Workforce Authorities Modernization Act
AMCP submits comments to CMMI on enhanced MTM model test strongly urging a delay in reporting timelines to Q4 2017.
AMCP Summary - Medicare Program; Part B Drug Payment Model
Testimony by AMCP member Eric Wright, PharmD, MPH at the U.S. Senate Finance Health Care Subcommittee Field Hearing on Opioid/HeroinAbuse in support of “Stopping Medication Abuse and Protecting Seniors” legislation
AMCP Submits Comments to CMS on 2017 Draft Call Letter
AMCP submits comments to Senate Finance Committee hearing on Opioids in support of S. 1913 - The Stopping Medication Abuse and Protecting Seniors Act.
AMCP Submits Comments for the Record on Subcommittee on Health Hearing on BPCIA Implementation.
AMCP commends CMS for its support of Senator Pat Toomey’s (R-PA) leadership in addressing the opioid epidemic and S.1913 - “The Stopping Medication Abuse and Protecting Seniors Act”
AMCP opposes Michigan HB 4812 which limits biologic drug substitution
AMCP submits comments to CDC on proposed opioid prescribing guidelines
AMCP provides comments to the Pharmacy Quality Alliance (PQA) on a new performance measure addressing adherence to long-acting inhaled bronchodilator agents in COPD patients